Certara, Inc. (NASDAQ:CERT) Stock Position Raised by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its holdings in Certara, Inc. (NASDAQ:CERT - Free Report) by 169.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,995,071 shares of the company's stock after purchasing an additional 1,253,385 shares during the quarter. Bank of New York Mellon Corp owned 1.24% of Certara worth $21,248,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Venturi Wealth Management LLC grew its stake in shares of Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after purchasing an additional 2,509 shares in the last quarter. Blue Trust Inc. grew its stake in shares of Certara by 20.9% in the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after purchasing an additional 822 shares in the last quarter. KBC Group NV grew its stake in shares of Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company's stock worth $57,000 after purchasing an additional 1,584 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Certara by 442.2% in the fourth quarter. GAMMA Investing LLC now owns 8,421 shares of the company's stock worth $90,000 after purchasing an additional 6,868 shares in the last quarter. Finally, Moloney Securities Asset Management LLC bought a new position in shares of Certara in the fourth quarter worth $128,000. Institutional investors own 73.96% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on CERT. Barclays raised their target price on Certara from $12.00 to $13.00 and gave the company an "equal weight" rating in a research note on Friday, February 28th. William Blair reaffirmed a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. TD Cowen began coverage on Certara in a research note on Thursday, February 27th. They set a "buy" rating and a $16.00 target price for the company. Finally, Stephens reaffirmed an "overweight" rating and set a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $15.83.

Remove Ads

Certara Stock Down 5.3 %

Certara stock traded down $0.58 during mid-day trading on Thursday, hitting $10.43. The company's stock had a trading volume of 1,092,667 shares, compared to its average volume of 992,727. The firm's 50 day moving average is $12.58 and its 200 day moving average is $11.56. The company has a market cap of $1.68 billion, a PE ratio of -52.15, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. Certara, Inc. has a 52-week low of $9.41 and a 52-week high of $19.22.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.